Open access · OA
via Europe PMC
Frailty, polypharmacy, deprescribing, and 23-hour activity: insights from a mouse model.
The journals of gerontology. Series A, Biological sciences and medical sciences · 2026
Abstract
Management of older people with frailty commonly includes polypharmacy and deprescribing. The impacts of frailty on the outcomes of medication use and deprescribing are poorly understood, as are the effects of medication use and deprescribing on frailty and function. Here, using aged C57BL/6J (B6) male mice, we explore the effects of different chronic drug regimens (polypharmacy and monotherapy) and deprescribing on daily activities using an automated behavioral recognition cage and explore the relationship with frailty and trajectories. At 12 months, male C57BL/6 mice were chronically administered a control diet, 1 of 5 monotherapy diets, or 1 of 3 polypharmacy diets with an increasing Drug Burden Index (measure of total exposure to sedative and anticholinergic medications). At 21 months of age, mice were stratified to continue treatment or to have treatment gradually withdrawn (deprescribed). At 24 months, mice were assessed using the Laboratory Animal Behavior Observation Registration and Analysis System (LABORAS) automated animal behavioral recognition system for 23 hours. We found that polypharmacy with increasing DBI substantially altered activity and could not be extrapolated from monotherapy response. After deprescribing, while some of the drug effects were reversible, others were irreversible, and we observed some novel changes. Exploring the relationship between frailty and LABORAS behavioral outcomes revealed unique correlations for each intervention group. Four key clusters were identified with different frailty trajectories and attributes, deficits, and LABORAS outcomes. This preclinical study demonstrates that medication use and deprescribing can impact activity, frailty, and frailty trajectories. The context of polypharmacy and deprescribing are important considerations to enhance translation of preclinical studies of frailty.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1093/gerona/glag170
- Canonical
- link ↗
- Fetched
- 2026-10-09 MST
Cite this
APA
J, M., K, W., & SN., H. (2026). Frailty, polypharmacy, deprescribing, and 23-hour activity: insights from a mouse model. <em>The journals of gerontology. Series A, Biological sciences and medical sciences</em>. https://doi.org/10.1093/gerona/glag170
Vancouver
J M, K W, SN. H. Frailty, polypharmacy, deprescribing, and 23-hour activity: insights from a mouse model. The journals of gerontology. Series A, Biological sciences and medical sciences. 2026. doi:10.1093/gerona/glag170.
BibTeX
@article{mach2026Frailt,
title = {Frailty, polypharmacy, deprescribing, and 23-hour activity: insights from a mouse model.},
author = {Mach J and Winardi K and Hilmer SN.},
journal = {The journals of gerontology. Series A, Biological sciences and medical sciences},
year = {2026},
doi = {10.1093/gerona/glag170},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Obesity Research & Clinical Practice 2024
Open access · CC-BY
Associations between body mass index, biological age and frailty in the critically ill
Maturitas 2026
Citation only
Longitudinal trajectories of the C-reactive protein-triglyceride-glucose index and frailty progression in two nationwide prospective cohorts.
The Journal of Frailty & Aging 2025
Open access · CC-BY
Developing an Electronic Frailty Index (eFI) and a biological age trajectory with a cohort of over one million older adults in Hong Kong
Drugs & Aging 2025
Open access · CC-BY
Frailty-Informed Pain Management: A Clinical Imperative Beyond Chronological Age
Samsung Medical Center 2012
Open access · US-GOV
Prognostic Impact of Frailty in Cardiogenic Shock: Nationwide Cohort Study
Clinical and Experimental Dermatology 2025
Citation only